TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vitamin D on Moderate to Severe Periodontitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age from 30 years old to 70 years old~2. More than 20 teeth remaining in the mouth~3. Clinical diagnosis of moderate to severe periodontitis~4. Not receiving periodontal treatment within 6 months~5. Not taking antibiotic drugs within 3 months.~Exclusion Criteria:~1. Diabetes, thyroid and parathyroid endocrine associated diseases~2. Severe systemic diseases, such as cancer~3. Taking vitamin D and / or calcium drugs during observation~4. Taking aspirin, non-steroidal anti-inflammatory drugs, and steroids~5. Pregnant or prepare to pregnant within one year~6. Have been suffering from hypercalcemia, malabsorption syndrome.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 2000IU/day (Type: EXPERIMENTAL): Subjects took 2000IU vitamin D per day
- 1000IU/day (Type: EXPERIMENTAL): Subjects took 1000IU vitamin D per day
- Placebo (Type: PLACEBO_COMPARATOR): Subjects took placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Cord Stimulation for Predominant Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SCS candidate with the Specify 5-6-5 surgical lead~* Has FBSS and does not require further surgery (defined as persistent or recurrent low back and leg pain of at least 6 months duration following at least one decompression and/or fusion procedure)~* Average low back pain is ≥ 5 as assessed by the baseline NPRS~* Average low back pain is greater than leg pain~* Subject has persistent moderate to severe low back and leg pain despite other treatments~Exclusion Criteria:~* Treated with SCS, subcutaneous or peripheral nerve stimulation, an intrathecal drug delivery system, requires back surgery at the location related to his/her original back pain complaint or experimental therapies~* Most recent back surgery \< 6 months ago~* Low back pain only (no leg pain)~* Investigator suspects substance abuse that might confound the study results~* Radiographic evidence of instability requiring fusion~* Pain relieved completely by lying down~* Life expectancy of \< 24 months~* Subject is pregnant or planning to become pregnant during the course of the study~* Subject is unable to undergo study assessments or complete questionnaires independently

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SCS + OMM (Type: ACTIVE_COMPARATOR): Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead plus an individual Optimal Medical Management (OMM) treatment plan
- OMM alone (Type: ACTIVE_COMPARATOR): The investigator and subject will determine an individual Optimal Medical Management (OMM) treatment plan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Pandemic Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults~Exclusion Criteria:~* History of Guillain-Barre syndrome or active neurological disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Positive blood culture during the study period.~* No positive blood cultures in prior 7 days~* Minnesota state research authorization provided~Exclusion criteria:~* No Minnesota state research authorization~* Deceased or transitioned to comfort care within 24 hours of enrollment~* Positive blood culture in prior 7 days~* Previously enrolled in this study~* Negative Gram stain

- Gender: ALL
- Minimum Age: None
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: EXPERIMENTAL): Standard Mayo practices (bacterial culture and susceptibility testing) will be used. FilmArray testing will not be performed.
- FilmArray test (Type: EXPERIMENTAL): Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.
- FilmArray plus antimicrobial stewardship (Type: EXPERIMENTAL): Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Able and willing to read, write, and understand the English language and provide English language written informed consent prior to beginning any study procedures.~* Age 18 to 70 years (inclusive) at the Screening Visit.~* A diagnosis of lumbosacral radicular pain (sciatica).~* Agrees to follow study-specific medication requirements.~* If sexually active and a female of child-bearing potential or a male capable of bearing a child, agrees to use an effective method of birth control during the study.~* Has reviewed all study specific materials and has, in the opinion of the Investigator, the abilities to understand and appropriately complete all study procedures.~Main Exclusion Criteria:~* Has radiologic evidence of a condition that would compromise study outcomes.~* Has ever had lumbosacral back surgery or plans to undergo spine surgical intervention while in the study.~* Has been diagnosed with insulin dependent diabetes mellitus.~* Presence of any other disorder, condition or circumstance (including secondary gain) that, in the opinion of the Investigator, has the potential to prevent study completion and/or to have a confounding effect on outcome assessments.~* Use of any investigational drug and/or device within 30 days, or is scheduled to receive an investigational drug other than blinded study drug during this study.~* Has a body mass index ≥40 kg/m2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SP-102 (Type: EXPERIMENTAL): SP-102

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of MV140

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women who gave their informed consent.~* Age between 18 and 75 years.~* Must be able to meet the dosage regimen.~* Subjects who had had at least 5 episodes of cystitis in the last 12 months.~* Subjects who had not responded to hygienic-sanitary measures and / or suppressive treatment and / or postcoital prophylaxis.~* Subjects who were free of urinary tract infections at the time of inclusion in the study.~Exclusion Criteria:~* Had not given their informed consent.~* Age was not within the established age range.~* Could not offer cooperation and/or had severe psychiatric disorders.~* Presented a pathologic post-micturition residue.~* Presented moderate to severe incontinence.~* Presented genital tumours.~* Presented Urinary tract tumours.~* Presented lithiasis.~* Presented alterations in the immune system.~* Presented complicated UTIs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MV140 I (Type: EXPERIMENTAL): The subjects will receive daily dose of MV140 during 6 months
- MV140 II (Type: EXPERIMENTAL): The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months
- Placebo (Type: PLACEBO_COMPARATOR): The subjects will receive daily dose of placebo during 6 month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of a New Diet for the Treatment of Obesity in the NHS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥18 years~* Male or female~* Body mass index ≥35kg/m2 with at least one obesity related co-morbidity~* Body mass index ≥40kg/m2 with or without an obesity related co-morbidity~* Eligible for treatment under the NHS~Exclusion Criteria:~* History of any medical, psychological or other condition, or use of any medications, which would either compromise the validity of the study or the safety of the participant~* English language fluency and comprehension insufficient to be able to participate in educational and group components of the programme~* Usual residence/place of work is sufficiently far from the study site or logistical/lifestyle factors mean that it is likely that the patient would be unable to attend for all sessions/components of the study~* Pregnancy or breast feeding~* Previous bariatric surgery~* Concurrent participation in another research study which would either compromise the validity of the study or the safety of the participant~* Previous participation in a study if the investigators judge that this would either compromise the validity of the study or the safety of the participant~* Unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I-SatPro (Type: EXPERIMENTAL): Patients in the I-SatPro group will attend I-SatPro patient group sessions and follow the I-SatPro weight loss programme
- Control (Type: ACTIVE_COMPARATOR): Patients in the control group will attend NHS Tier 3 patient group sessions and follow the NHS Tier 3 weight loss programme

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Antibiotic-induced diarrhea~* Positive fecal analysis for Clostridium difficile toxin~Exclusion Criteria:~* Antibiotic treatment~* Probiotic treatment~* Intestinal infection other than Clostridium difficile~* Inflammatory bowel disease (Ulcerative colitis, Crohn's disease~* Immunodeficiency (drug- och disease-related)~* Pregnancy~* Unable to accept endoscopic procedures~* Unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vancomycin (Type: ACTIVE_COMPARATOR): Secondary treatment for relapse of Clostridium difficile infection.
- Cultured human intestinal microbiota1 (Type: EXPERIMENTAL): Cultured intestinal microbiota is experimental treatment for relapse of Clostridium difficile infection.
- Cultured human intestinal microbiota2 (Type: EXPERIMENTAL): Cultured intestinal microbiota is thirdly experimental treatment for second relapse of Clostridium difficile infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are hospitalized or in the process of being admitted to hospital and have an initial laboratory determination of current COVID-19 infection less than or equal to (≤)72 hours prior to randomization~* Are men or non-pregnant women~* Women of childbearing potential must agree to use at least one highly effective form of contraception for the entirety of the study~* Agree to the collection of nasopharyngeal swabs and venous blood~Exclusion Criteria:~* Require mechanical ventilation or anticipated impending need for mechanical ventilation~* Received convalescent COVID-19 plasma treatment prior to enrollment~* Were resident in a nursing home or long-term care facility immediately prior to current hospitalization~* Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product~* Have an oxygen saturation (SpO2) less than (\<)88 percent (%) while breathing room air at rest at randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LY3819253 (Type: EXPERIMENTAL): Participants received single doses of 700 milligrams (mg), 2800 mg or 7000 mg LY3819253 administered as intravenous infusion.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received single dose of Placebo as intravenous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Cognitive Remediation in a Supported Education Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment in the George Brown Redirection Through Education program.~* A DSM-IV chart diagnosis of schizophrenia or other psychotic condition~* Stable use of medications for at least 3 months without plans of changing medications.~* Proficiency in English.~Exclusion Criteria:~* a psychiatric history of mental retardation, brain injury, or other neurological condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive Remediation and Supported Education (Type: EXPERIMENTAL): Participants in this group will receive cognitive remediation training in addition to supported education. Cognitive remediation has two components: computer-based cognitive exercise sessions held on a twice weekly basis for 10 weeks as well as 10 weekly group discussion sessions (approximately 60 minutes in duration).
- Supported Education Only (Type: ACTIVE_COMPARATOR): The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness (see http://www.georgebrown.ca/marketing/FTCal/access/C702.aspx for a full description). Participants in this arm will receive all services and supports provided by this program. However, they will not receive the additional cognitive remediation training provided to those randomized to the experimental arm of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* newly diagnosed or diagnosis of relapsing (relapsed \<= 6 weeks to baseline) mild to moderate ulcerative colitis~* women not of childbearing potential or WOCP who agreed to use an effective contraceptive method~Exclusion Criteria:~* severe ulcerative colitis or relapsed for \> 6 weeks prior to baseline~* subjects who had relapsed on maintenance therapy with doses of mesalazine \> 2.0 g/day~* subjects with Crohn's disease, proctitis, bleeding disorders or active peptic ulcer disease~* subjects with asthma if they were known to be mesalazine-sensitive~* subjects who were at immediate or significant risk of toxic megacolon~* subjects who had previous resective colonic surgery~* subjects who had moderate or severe renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug and Non-Drug Treatment Of Severe Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 65 years~* Diagnosis of migraine with or without aura (International Classification of Headache Disorders)~* 3 or more migraine episodes/month with disability for the past 6 months~* Less than 20 total headache days/month for the past 6 months~Exclusion Criteria:~* Medication overuse headaches~* Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw~* Concurrently undergoing counseling/psychotherapy treatment~* Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual.~* Unable/unwilling to give written informed consent~* History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic abdominal syndromes, peripheral vascular disease.~* Uncontrolled hypertension at screening (sitting systolic pressure \> 160 mmHg, diastolic pressure \> 95 mmHg)~* Fertile female who is breastfeeding, pregnant planning a pregnancy within the next year or is unwilling to use adequate contraception.~* Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or multiple risk factors for heart disease), angina pectoris, documented silent ischemia, or cardiac arrythmias requiring medication, or a clinically significant EKG abnormality.~* Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)~* Has a substance abuse problem or a psychological disorder that prevents participation in study (e.g., unmanaged severe depression that requires immediate treatment or limits participation in home-based treatment)~* Hypersensitivity, intolerance or contraindication to use of Propranolol, Nadolol, Sumatriptan, or Rizatriptan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Optimal Acute Therapy plus Beta Blocker Placebo
- 2 (Type: ACTIVE_COMPARATOR): Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)
- 3 (Type: ACTIVE_COMPARATOR): Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker placebo
- 4 (Type: ACTIVE_COMPARATOR): Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Linaclotide for Capsule Endoscopy Preparation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Schedule for video endoscopy at UVHS~* Ability to speak, read and write English~* Age \>18~* Able to provide consent~Exclusion Criteria:~* Prisoner~* Woman who is currently pregnant or breastfeeding~* Allergy to linaclotide~* Patients with known or suspected mechanical gastrointestinal obstruction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Linaclotide 290mcg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete